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Abstract
Background: Seroconversion rates reported after Hepatitis B virus (HBV) vaccination globally
ranges from 85–90%. Health care workers (HCWs) are at high risk of acquiring HBV and non
responders' rates after HBV vaccination were not reported previously in Pakistani HCWs.
Therefore we evaluated immune response to HBV vaccine in HCWs at a tertiary care hospital in
Karachi, Pakistan.
Methods: Descriptive observational study conducted at Aga Khan University from April 2003 to
July 2004. Newly HBV vaccinated HCWs were evaluated for immune response by measuring serum
Hepatitis B surface antibody (HBsAb) levels, 6 weeks post vaccination.
Results: Initially 666 employees were included in the study. 14 participants were excluded due to
incomplete records. 271 (41%) participants were females and 381(59%) were males. Majority of the
participants were young (<25–39 years old), regardless of gender. Out of 652 HCWs, 90 (14%)
remained seronegative after six weeks of post vaccination. The percentage of non responders
increased gradually from 9% in participants of <25, 13% in 25–34, 26% in 35–49, and 63% in >50
years of age. Male non responders were more frequent (18%) than female (8%).
Conclusion: Seroconversion rate after HBV vaccination in Pakistani HCWs was similar to that
reported in western and neighboring population. HCWs with reduced immune response to HBV
vaccine in a high disease prevalent population are at great risk. Therefore, it is crucial to check post
vaccination HBsAb in all HCWs. This strategy will ensure safety at work by reducing nosocomial
transmission and will have a cost effective impact at an individual as well as at national level, which
is very much desired in a resource limited country.
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Background
Hepatitis B virus (HBV) infection and its sequelae, includ-
ing chronic liver disease, cirrhosis and hepatocellular car-
cinoma are major global health problems. About 350
million chronic carriers world wide constitute the primary
reservoir of infection [1]. Exposure to blood and body flu-
ids is a major risk factor for development of HBV infection
and it is a well established fact that in an unvaccinated
individual, the risk of acquisition of HBV infection after
single exposure of HBV infected blood or body fluid
ranges from 6%-30%. Therefore health care workers
(HCWs) are at high risk of HBV infection due to repeated
exposure [2-4]. In addition non-existing infection control
activities and higher prevalence of HBV in our region fur-
ther augment the risk of nosocomial transmission of HBV
to HCWs.
With the availability of HBV vaccine since 1982, the
decline in the incidence of HBV infection and associated
morbidity and mortality was reported [5-8]. Therefore, in
1997 CDC recommended that all HCWs should be vacci-
nated against HBV [9]. Despite the recommendation and
excellent protection profile among post vaccinated per-
sonnel, compliance to this recommendation remained
poor in various health care settings [10,11].
Immune response to HBV vaccine is assessed by measur-
ing antibody level after 6–8 weeks of completion of 3
doses. Hepatitis B surface antibody higher than10 mIU/
ml is generally taken to be protective [12,13]. Factors asso-
ciated with decreased immune response include increas-
ing age, smoking, obesity, gender and genetic factors [14-
16]. Previous studies on HCWs published from various
parts of the world have reported 12–21% non responders
to HBV vaccine (Table 1). Despite HBV infection being a
major health care issue in both community and nosoco-
mial settings in Pakistan, data assessing immune response
in HCWs is unavailable. Considering a prevalence rate of
3–4% in general population [17] possibility of nosoco-
mial transmission in a health care setting is considerable.
Therefore, we conducted this study at Aga Khan University
Hospital (AKUH) to evaluate the immune response
among health care personnel after completion of their
vaccination schedule.
Methods
This descriptive observational study was conducted at
AKUH, Karachi, Pakistan from April 2003 to July 2004.
AKUH is a 550 bedded tertiary care referral centre with
approximately 4000 HCWs.
Newly inducted HCWs in the hospital were immunized
with recommended three doses of HBV vaccine as per
institutional policy. Immunization was done with recom-
binant vaccine (Engerix B – Glaxo SmithKline Biological)
and the standard vaccination schedule (0, 1, 6 months)
was followed. Adult dose with 20 mcg of hepatitis B sur-
face antigen per ml was administered intramuscularly
over deltoid region. Hepatitis B surface antibody (HBsAb)
level was measured (AUSAB® Abbott AXSYM system –
MEIA) after 6–8 weeks of completion of vaccination
course. Previously immunized and HBsAb reactive
employees were excluded from the study.
Baseline vaccination was the exposure given to HCWs and
the development of antibodies was considered as the out-
come variable. HCWs with antibody titers of ≥10 mIU/ml
were considered responders while those with levels <10
mIU/ml were labeled as non-responders. Age and gender
were included as confounding variables. Study popula-
tion was divided into four age groups; group1: <25 years,
group2: 25–34 years, group3: 35–49 years and group4:
>50 years (Figure 1).
Data was entered and statistical analysis was performed in
SPSS version 13.0.1. In descriptive analysis percentages of
categorical variables (gender, antibody titer level and age
groups) were reported. Bivariate comparisons were
assessed using chi-square test and logistic regression. Mul-
tivariable logistic regression analysis was run to adjust for
the confounders. A p-value of < 0.05 was considered as
statistically significant.
Table 1: Immune response after hepatitis B vaccine in different populations of world
Author Year of publication Country Non responders after immunization (%)
Roome A J et al [16] 1993 JAMA USA (Connecticut) 11.9%
Averhoff F et.al [20] 1998 Am J Prev Med. USA(Georgia) 12%
Louther J et.al [21] 199 Am J Infec Control USA(New York) 21%
Platkov.E et.al [22] 2003 Int. J. Occup Med Environ Health ISRAEL (Netanya) 13.5%
Luiz A.S et.al [23] 2005 The Brazilian Journal of Infectious Diseases BRAZIL(Sao Paulo) 13.6%
Yen YH et.al [24] 2005 Liver international TAIWAN(Kaohsiung) 13.6%
SaberifIroozi M et.al [25] 2006 Arch. Iran Med IRAN(SHIRAZ) 12.7%BMC Infectious Diseases 2007, 7:120 http://www.biomedcentral.com/1471-2334/7/120
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Results
Initially a total of 666 HCWs were enrolled. However by
the end of the study period, 14 participants were excluded
due to incomplete records. Majority (62.3%) of the HCWs
were enrolled in the year 2003 and all others in the year
2004. Female participants were 271 (41%) and male were
381 (59%). Over all, 14% of the HCWs after 6–8 weeks of
completion of immunization with HBV vaccine did not
develop any antibody response and were labeled as non
responders. (Figure 1).
The bivariate analysis in Table 2 shows that the frequency
of nonresponders was higher in males in comparison to
females (OR = 2.50) (p = 0.001) and decline in immune
response was noticed with increasing age. (OR = 1.54,
3.58, 17.80) (p = 0.001).
Multivariate analysis also revealed decrease seroconver-
sion in male gender in comparison to females (OR = 2.1,
95%CI = 1.2–3.5). HCWs especially with the age groups
of ≥50 years (OR = 14.6, 95%CI = 3.9–54.6) and 35–49
years (OR = 3.0, 95%CI = 1.5–5.9) showed significantly
reduced immune response in comparison to the young
HCWs (<25 years).
Discussion
This is the first study from Pakistan and provides the local
epidemiological data assessing the immune response to
HBV vaccine in HCWs. In this study, 14% of HCW
remained nonresponders i.e. the serum protective level of
≥10 mIU/ML of HBsAb was not achieved after recom-
mended routine HBV vaccination.
Age and gender were the two variables included in our
study. The percentage of male nonresponders (18%) was
more than twice of the female (8%) counterpart (p  =
0.0001) (Table 2). This finding was in concordance with
Wood et al that reported a response rate of 18% and 9%
respectively in male and female (p = 0.006)[15]. Smoking
and certain genetic factors have been reported as probable
reasons of decreased immune response in male. However
we have not evaluated these factors in our study.
Descriptive Characteristics of study participants Figure 1
Descriptive Characteristics of study participants.
Descriptive Characteristics of study participants
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Highest rate of immune response (91%) was observed in
younger HCWs (<25 years) which started to decline with
increasing age (p = 0.0001). Only 36% of HCWs of group
4 (> 50 years of age) developed response to HBV vaccine,
however the sample size in this group was very small
(Table 2). The findings are more or less in the agreement
with earlier reports. Roome et al. also observed the inade-
quate levels of antibodies in relation to increasing age,
from 2.8% among those younger than 30 years to 42.1%
among those older than 60 years (p < 0.0001) of age [16].
The observation favors the hypothesis that with increasing
age seroprotective antibody formation after vaccination is
decreased. This finding is of great clinical significance as
non-responders remain susceptible to HBV infections.
Therefore, from infection control perspective, the post
vaccination HBsAb levels should be determined for all
HCWs.
Multivariate analysis also favored age and gender as an
independent risk factor for nonresponders. (Table 3)
In the past there was no data available regarding the
immune response after HBV vaccination in HCWs from
Pakistan. However studies from different part of the world
have reported the immune responses to HBV vaccine in
their HCWs. Seroconversion rates in Pakistani HCWs cor-
related with previous studies conducted in USA, Israel,
Brazil and Taiwan (Table 1).
The major limitation of this study is the inability to eval-
uate the hepatitis B core antibody (antiHBc) in our study
population due to low budget and limited resources.
Therefore there is a possibility that reduced immune
response to HBV vaccine was due to occult hepatitis B
infection. We agree that a non responder rate of 14%
might be an over estimate in our study population; how-
ever in a resource limited setting our results are providing
a baseline for future epidemiological studies in this area.
Moreover our finding matched with the studies conducted
in other countries. Second limitation of our study was that
we were not able to evaluate the association of decreased
immune response with risk factors other than age and
gender. Previous studies suggested that smoking, obesity,
nutritional status, site of administration of vaccine and
genetic factors also contributed to reduced immune
response.
Table 2: Bivariate analysis of nonresponders in different genders and age groups (n = number)
CHARACTERISTICS NORMAL RESPONDERS NONRESPONDERS OR p-VALUE
n (%) n (%)
GENDER n (%)
FEMALE 249 (92) 22 (8) 1
MALE 313 (82) 68 (18) 2.5 <0.001
AGE GROUP n (%)
<25 years 234 (91) 23 (9) 1 -
25–34 years 270 (87) 41 (13.0) 1.5 0.114
35–49 years 54 (74) 19 (26) 3.6 <0.001
≥50 years 4 (36) 7 (63) 17.8 <0.001
Table 3: Multivariate comparison of non-responders with normal responders
CHARACTERISTICS OR p-value
Gender
Female 1.0 -
Male 2.1 0.006
AGE GROUP (n)
<25 years 1.0 -
25–34 years 1.4 0.254
35–49 years 3.0 0.002
≥50 years 14.6 <0.001BMC Infectious Diseases 2007, 7:120 http://www.biomedcentral.com/1471-2334/7/120
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Post vaccination testing is recommended for high risk per-
sons, including health-care and public safety workers;
chronic hemodialysis patients, HIV-infected persons, and
other immunocompromised persons, and sex or needle-
sharing partners of HBsAg-positive persons. However this
practice is usually not followed in majority of hospitals in
Pakistan [18,19].
In health care settings pre-exposure vaccination pro-
grammes are not only important for safety of HCWs but
are also proven cost effective relative to post exposure
prophylaxis with hyperimmunoglobulins. The difference
between the cost of HBV vaccine and HBV immunoglob-
ulin is enormous as three doses of HBV vaccine cost
around 17 US $, and the cost of immunoglobulin ranges
from 416–800 US $. This extra cost is borne by the insti-
tutions or the HCWs, which is an economical burden
especially in developing countries.
Conclusion
We concluded from this study that the seroconversion rate
after completion of scheduled vaccination was more or
less similar in our HCWs in comparison to HCWs working
in other parts of the world, with similar age and gender
variability. There is a need to strictly implement the policy
of hepatitis B immunization in every health care setting,
as recommended by CDC. It is also extremely important
to check the post vaccination status of all HCWs after 6–8
weeks of vaccination as it not only ensures safety of
employees but also reduces rate of transmission hence
functioning as a cost effective exercise at individual as well
as national level.
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